Resistant Hypertension - Pipeline Review, H2 2016 - Key Players are Bayer AG, Novartis AG, Sarfez Pharmaceuticals, PhaseBio Pharmaceuticals & Zumbro Discovery - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Resistant Hypertension - Pipeline Review, H2 2016" report to their offering.

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications.

This report provides comprehensive information on the therapeutic development for Resistant Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Hypertension and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Bayer AG
  • Novartis AG
  • Sarfez Pharmaceuticals Inc
  • PhaseBio Pharmaceuticals Inc
  • Zumbro Discovery Inc

Key Topics Covered:

  1. Introduction
  2. Resistant Hypertension Overview
  3. Therapeutics Development
  4. Pipeline Products for Resistant Hypertension - Overview
  5. Pipeline Products for Resistant Hypertension - Comparative Analysis
  6. Resistant Hypertension - Therapeutics under Development by Companies
  7. Resistant Hypertension - Therapeutics under Investigation by Universities/Institutes
  8. Resistant Hypertension - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Resistant Hypertension - Products under Development by Companies
  13. Resistant Hypertension - Products under Investigation by Universities/Institutes
  14. Resistant Hypertension - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/5dlwmj/resistant

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs